Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT04408638 2026-01-07

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 3 Active not recruiting

270 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Phase 1 Active not recruiting

14 enrolled

BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

NCT04691817 2026-01-07

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Phase 1/2 Recruiting

28 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06043674 2026-01-07

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Phase 2 Recruiting

70 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03533283 2026-01-06

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1/2 Active not recruiting

211 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT04395222 2026-01-06

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Phase 2 Active not recruiting

21 enrolled 15 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT04910568 2025-12-24

CAMMA 1

Phase 1 Active not recruiting

126 enrolled

Plasma cell

Multiple Myeloma

NCT03337698 2025-12-12

Morpheus Lung

Phase 1/2 Completed

314 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06251076 2025-12-10

Plan Development for Giving Teclistamab in the Outpatient Setting

Phase 4 Recruiting

15 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT03564340 2025-12-03

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Phase 1/2 Recruiting

890 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Phase 1/2 Completed

341 enrolled 28 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT04729959 2025-10-20

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Phase 2 Active not recruiting

59 enrolled

CNS

Astrocytoma, Glioblastoma

NCT04007029 2025-09-05

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Active not recruiting

24 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03677154 2025-08-21

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

188 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04377659 2025-05-28

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Phase 2 Terminated

9 enrolled 8 charts

COVID-19, Respiratory Tract Infections

NCT06016179 2025-05-22

RIOT2

Phase 1 Recruiting

12 enrolled

Thoracic

Pleural Effusion, Malignant

NCT03821246 2025-05-15

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Phase 2 Recruiting

68 enrolled

Genitourinary

Prostatic Neoplasms

NCT03434730 2025-04-22

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Phase 2 Completed

46 enrolled

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT05619744 2025-03-10

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Phase 1 Completed

41 enrolled

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT04370834 2025-02-04

Tocilizumab for Patients With Cancer and COVID-19 Disease

Phase 2 Terminated

1 enrolled 10 charts

Other hematologic neoplasm

Pneumonia, Respiratory Distress Syndrome, Hematologic Neoplasms

NCT03708224 2025-01-28

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Phase 2 Recruiting

55 enrolled

Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms

NCT03467373 2025-01-17

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Phase 1 Completed

111 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03677141 2024-12-18

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

117 enrolled 26 charts

Lymphoid

Lymphoma, B-Cell

Clinical Trials

Morpheus-panBC

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

SUNMO

iMATRIX GLO

PLYCOM

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

MorningSun

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

GLOBRYTE

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

MORPHEUS-LIVER

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Tocilizumab in Children With ACP

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

CAMMA 2

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

CAMMA 1

Morpheus Lung

Plan Development for Giving Teclistamab in the Outpatient Setting

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

RIOT2

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Tocilizumab for Patients With Cancer and COVID-19 Disease

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma